Description Proper Usage Precautions Possible Side effects
ChemicalBook > CAS DataBase List > Solifenacin succinate

Solifenacin succinate

Description Proper Usage Precautions Possible Side effects
Product Name
Solifenacin succinate
CAS No.
242478-38-2
Chemical Name
Solifenacin succinate
Synonyms
CS-353;Vesikur;vesicare;YM 67905;Solfenacin;42478-38-2;IsoprenalinoeSulfate;solifenacin succinate;Solefinacin Succinate;Sophenazine succinate
CBNumber
CB3500859
Molecular Formula
C27H32N2O6
Formula Weight
480.56
MOL File
242478-38-2.mol
More
Less

Solifenacin succinate Property

Melting point:
~145°
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
Methanol (Slightly, Heated, Sonicated), Water (Slightly, Sonicated)
form 
Solid
color 
White to Off-White
optical activity
[α]/D +35 to +45°, c =1 in H2O
Water Solubility 
H2O: 2mg/mL, clear
Merck 
14,8712
Stability:
Hygroscopic
CAS DataBase Reference
242478-38-2(CAS DataBase Reference)
More
Less

Safety

RTECS 
NW7136000
HS Code 
29339900
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

TCI Chemical
Product number
S0944
Product name
Solifenacin Succinate
Purity
>98.0%(HPLC)
Packaging
25mg
Price
$63
Updated
2024/03/01
TCI Chemical
Product number
S0944
Product name
Solifenacin Succinate
Purity
>98.0%(HPLC)
Packaging
100mg
Price
$161
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
10mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
25mg
Price
$48
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
50mg
Price
$86
Updated
2024/03/01
More
Less

Solifenacin succinate Chemical Properties,Usage,Production

Description

Solifenacin succinate is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence.

Proper Usage

  1. This medication should be taken with liquids and swallowed whole. It may be taken with or without food.
  2. Take only the amount of this medication that has been prescribed for you by your doctor; taking more than the prescribed amount can cause adverse effects.
  3. If you miss a dose of this medication, begin taking it again the next day. Do not take two doses of solifenacin succinate in the same day.

Precautions

  1. Individuals with any of the following medical problems should not take this medication: urinary retention, gastric retention, narrow angle or uncontrolled glaucoma, or severe kidney problems. Solifenacin succinate can aggravate each of these conditions.
  2. Solifenacin succinate may cause blurred vision; do not engage in potentially dangerous activities such as driving until you know the effect of the medication on your vision.
  3. This medication, like all anticholinergic medications, may cause drying of the mouth. Since continued dryness of the mouth can increase the risk of dental disease, alert your dentist if you are taking this medication.
  4. Like all anticholinergic medications, solifenacin succinate can cause or worsen constipation.
  5. Because of decreased sweating, this medication can cause heat prostration when used in a very hot environment.
  6. This medication has not been studied in pregnant women. However, it has been shown in animal studies to impact preand postnatal development. If you are pregnant, or planning to become pregnant, do not start this medication before you have discussed it with your physician.
  7. It is not known whether solifenacin succinate passes into breast milk. Women who taking this medication and wish to breastfeed should discuss it with their physician.

Possible Side effects

  1. Side effects that are expected with this type of medication and do not require medical attention unless they continue or are bothersome: dry mouth; dry eyes; constipation, blurred vision, difficult urination.
  2. Less common side effect that should be reported to your physician: severe abdominal pain.
  3. Symptoms of overdose: severe central anticholinergic effects, including blurred vision; clumsiness or unsteadiness; confusion; seizures; severe diarrhea; excessive watering of the mouth; increasing 240 Multiple Sclerosis: A Self-Care Guide to Wellness muscle weakness (especially in the arms, neck, shoulders, and tongue); muscle cramps or twitching; severe nausea or vomiting; shortness of breath; slow heartbeat; slurred speech; unusual irritability, nervousness, or restlessness; unusual tiredness or weakness.

Description

Solifenacin is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification. The pooled results of four phase III trials concluded that 63% of women receiving 5mg of solifenacin once daily and 68% of women receiving 10mg once daily reported a 50% or more reduction in urgency episodes, compared to 44% of women taking placebo. This compares with a 53% reduction in patients receiving tolterodine twice daily. In another placebo-controlled trial, with the change in the number of micturitions in a 24-h period as the primary endpoint, once-daily solifenacin recorded an 18% decrease for a 5-mg dose and a 21% decrease for a 10-mg dose compared to 10% with placebo. Pharmacokinetic studies have demonstrated that solifenacin has an oral bioavailability of 90%, a long elimination half-life (50 h), low clearance (9.39 L/h), a mean Vss of 599 L, a Cmax of approximately 14 ng/mL, and a time to maximal plasma concentration of 4 h making it suitable for q.d. dosing. Furthermore, these PK parameters are not affected by food ingestion. Solifenacin is excreted predominantly in the feces with only 3–6% found in urine. It is contraindicated in patients with hepatic impairment, gastric retention, urinary retention, or uncontrolled narrow angle glaucoma. Further precautions, such as dose adjustment, should be considered for patients with concurrent use of ketoconazole or other potent CYP3A4 inhibitors or for patients with a history of QT prolongation or currently on medications known to prolong the QT interval. Finally, while other muscarinic antagonists have been explored in the treatment of irritable bowel syndrome (IBS), it is too early to predict the therapeutic utility of solifenacin for IBS although animal studies are promising.

Chemical Properties

White Solid

Originator

Yamanouchi (Japan)

Uses

Muscarinic M3 receptor antagoinst. Used in treatment of urinary incontinence.

Uses

sedative

Uses

Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

Definition

ChEBI: Solifenacin succinate is a member of isoquinolines.

brand name

Vesicare (Astellas).

General Description

Solifenacin succinate (Vesicare),(+)-(1S, 3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, is a competative antagonistfor M1, M2, and M3 receptor subtypes. One of the issues surroundingthe use of such antagonists is the selectivity for thebladder over other tissue such as the salivary glands. It isreported that the selectivity of solifenacin for bladder muscarinicreceptors over salivary receptors is superior to theeffects observed with oxybutynin.

Clinical Use

Selective M3 antimuscarinic
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency

in vitro

in radioligand receptor binding assay, the kivalues of solifenacin for human muscarinic m1, m2, m3, m4and m5receptors were 26, 170, 12, 110 and 31 nm, respectively. in isolated rat urinary bladder, solifenacin competitively antagonized carbachol-induced contractions, with a pa2value of 7.44±0.09[3].in bladder smooth muscle cells and salivary gland cells isolated from rats, solifenacin and the other antimuscarinic drugs inhibited carbachol-induced increases in intracellular ca2+levels in a concentration-dependent manner. thepki was 8.12for bladder smooth muscle cells, 3.6-fold more potent than that for salivary gland cells (pki=7.57) [1].

in vivo

in anesthetized rats, solifenacin dose-dependently inhibited carbachol-induced intravesical pressure elevation and salivary secretion, and exhibited selectivity (3.7- to 6.5-fold) for urinary bladder over salivary gland [1]. in anesthetized rats, solifenacin and oxybutynin increased the maximum bladder capacity in a dose-dependent manner and also decreased the maximum intravesical pressure [3].in healthy young men, multidose study evaluated doses. in the single-dose of solifenacin succinate (5-, 10-, 20-, and 30-mg), mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively.in the multidose study, the ranges were 2.9 to 5.8 and 45.0 to 64.8, respectively. the single-dose administration was well tolerated. the common adverse events were dry mouth, blurred vision, and headache [4].

Drug interactions

Potentially hazardous interactions with other drugs
Avoid if GFR<30 mL/min if also taking itraconazole, ketoconazole or ritonavir.
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

Metabolism

Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4 and is excreted mainly as metabolites in urine and faeces.

References

[1]. ohtake a, ukai m, hatanaka t, et al. in vitro and in vivo tissue selectivity profile of solifenacin succinate (ym905) for urinary bladder over salivary gland in rats[j]. european journal of pharmacology, 2004, 492(2): 243-250.
[2]. yang j, williams j a, yule d i, et al. mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization[j]. molecular pharmacology, 1995, 48(3): 477-485.
[3]. ohtake a, saitoh c, yuyama h, et al. pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents[j]. biological and pharmaceutical bulletin, 2007, 30(1): 54-58.
[4]. smulders r a, krauwinkel w j, swart p j, et al. pharmacokinetics and safety of solifenacin succinate in healthy young men[j]. the journal of clinical pharmacology, 2004, 44(9): 1023-1033.
[5]. cardozo l, lisec m, millard r, et al. randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder[j]. the journal of urology, 2004, 172(5): 1919-1924.

Solifenacin succinate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Solifenacin succinate Suppliers

Canada 3 China 368 Czech Republic 1 Europe 1 France 3 Germany 3 Greece 1 India 102 Israel 2 Italy 2 Japan 2 Malaysia 1 Malta 1 Mexico 2 Nepal 1 Philippines 1 Poland 1 South Korea 6 Spain 6 United Arab Emirates 1 United Kingdom 4 United States 34 Global 546
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19881
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38631
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
SynFine Research
Tel
--
Fax
--
Email
research@synfine.com
Country
United States
ProdList
1024
Advantage
68
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Jubilant Pharma Holdings Inc.
Tel
--
Fax
--
Email
bd.api@jubl.com
Country
United States
ProdList
39
Advantage
58
Amarantine Pharmaceuticals LLC
Tel
--
Fax
--
Email
info@amarantinepharma.com
Country
United States
ProdList
16
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
Interchem Corporation USA
Tel
--
Fax
--
Email
esa@interchem.com
Country
United States
ProdList
469
Advantage
58
Byron Chemical Company, Inc
Tel
--
Fax
--
Email
bcc@byronchemical.com
Country
United States
ProdList
88
Advantage
58
International Specialty Chemicals & Pharmaceuticals, Inc. (ISC&P)
Tel
--
Fax
--
Email
info@ischem.com
Country
United States
ProdList
77
Advantage
58
Genegobio Inc.
Tel
--
Fax
--
Email
mark@genegobio.com
Country
United States
ProdList
195
Advantage
0
SST Corporation
Tel
--
Fax
--
Email
info@sst-corp.com
Country
United States
ProdList
237
Advantage
38
SHAMROCK INDUSTRIAL CO. LTD.
Tel
--
Fax
--
Email
pharma@shamrockindia.com
Country
United States
ProdList
119
Advantage
43
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
MICRO LABS LTD
Tel
--
Fax
--
Email
calibration@microlabs-inc.com
Country
United States
ProdList
36
Advantage
58
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
More
Less

View Lastest Price from Solifenacin succinate manufacturers

Sinoway Industrial co., ltd.
Product
Solifenacin Succinate 242478-38-2
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
99% up, High Density
Supply Ability
20 tons
Release date
2022-07-19
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Solifenacin succinate 242478-38-2
Price
US $0.00/KG
Min. Order
1KG
Purity
99.0
Supply Ability
10KG/month
Release date
2021-07-03
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Solifenacin Succinate 242478-38-2
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-09-29

242478-38-2, Solifenacin succinateRelated Search:

Metroprolol succinate PHENYL VALERATE Fexofenadine Solifenacin Diethyl succinosuccinate Isoquinoline Succinic acid iron succinate Acetonylsuccinic acid diethyl ester Fexofenadine hydrochloride Sumatriptan Succimer Dimethyl succinate Disodium succinate 6alpha-Methylprednisolone sodium succinate SOLIFENACIN PHENYL RESIN Solifenacin Related Compound 18

  • VESICARE; YM905; YM-905; YM 905
  • CS-353
  • Solifenacin for System Suitability
  • 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate butanedioic acid
  • vesicare
  • solifenacin succinate
  • IsoprenalinoeSulfate
  • Solefinacin Succinate
  • Butanedioic acid, compd. with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
  • (1R,3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
  • (1S)-(3R)-1-Azabicyclo[2.2.2]oct-3-yl 3,4-Dihydro-1-phenyl-2(1H)- isoquinolinecarboxylate Butanedioic Acid
  • Vesikur
  • YM 67905
  • Solifenacin succinate(Vesicare)
  • Solifenacin Succinate API
  • Solifenacin succinate, >=98%
  • Solifenacin Succinate 1
  • Solfenacin
  • (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate monosuccinate
  • 3,4-Dihydro-1-phenyl-2(1H)- isoquinolinecarboxylate Butanedioic Acid
  • (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate monosuccinat
  • Solifenacin succinate, 98%, a muscarinic receptor antagonist
  • 1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 1-azabicyclo[2.2.2]octan-3-yl ester
  • 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid (Solifenacin?Succinate)
  • Solifenacin for system suitability CRS
  • Solifenacin succinate CRS
  • Solifenacin Succinate &gt
  • (S)-(R)-Quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate succinate
  • Solifenacin succinate USP/EP/BP
  • 42478-38-2
  • Solifenacin succinate (YM905)
  • Solifenacin for system suitability(Y0001743)
  • Solifenacin succinate (Y0001763)Q: What is Solifenacin succinate (Y0001763) Q: What is the CAS Number of Solifenacin succinate (Y0001763) Q: What are the applications of Solifenacin succinate (Y0001763)
  • Solifenacin Succinate (1615300)
  • Sophenazine succinate
  • Solifenacin Succinate EP
  • Solifenacin Succinate / (S,R)-Solifenacin Succinate
  • Solifenacin succinate, 10 mM in DMSO
  • 242478-38-2
  • 2424-38-2
  • 24278-38-2
  • 42478-38-2
  • C23H26N2O2C4H6O4
  • C23H26N2OC4H6O4
  • Solifenacin
  • API